{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_7000", "batch_size": 200, "batch_pos": 173, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain a high-potency verb or potent metaphor.", "method": "llm_batch", "batch_id": "batch_2_17512", "batch_size": 200, "batch_pos": 141, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment describes a future event ('would begin in 2025'), not realised impact.", "method": "llm_batch", "batch_id": "batch_3_20476", "batch_size": 200, "batch_pos": 78, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "Segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_8652", "batch_size": 200, "batch_pos": 67, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment reports a timeline for testing, which is not an explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_19200", "batch_size": 200, "batch_pos": 62, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser token combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_20320", "batch_size": 200, "batch_pos": 19, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_5536", "batch_size": 200, "batch_pos": 1, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes planned future activity related to development/testing: 'late-stage testing would begin in 2025'.", "method": "llm_batch", "batch_id": "batch_8_17400", "batch_size": 200, "batch_pos": 185, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
